A Comparative Evaluation of Glycopyrronium Bromide, A Long-Acting Muscarinic Antagonist versus Tiotropium Bromide in Triple Therapy of COPD Patients in an Indian Clinical Setting

Aleemuddin Naved; Humaira Minhaj; Ayemen Fatima; Aisha Begum; Syeda Zuleqaunnisa Begum

doi:10.5005/ijcdas-63-1-29

SEARCH WITHIN CONTENT

Online First

A Comparative Evaluation of Glycopyrronium Bromide, A Long-Acting Muscarinic Antagonist versus Tiotropium Bromide in Triple Therapy of COPD Patients in an Indian Clinical Setting

Aleemuddin Naved, Humaira Minhaj, Ayemen Fatima, Aisha Begum, Syeda Zuleqaunnisa Begum

Keywords : COPD, Glycopyrronium bromide, Tiotropium bromide, Bronchodilator, Long-acting muscarinic antagonist

Citation Information : Naved A, Minhaj H, Fatima A, Begum A, Begum SZ. A Comparative Evaluation of Glycopyrronium Bromide, A Long-Acting Muscarinic Antagonist versus Tiotropium Bromide in Triple Therapy of COPD Patients in an Indian Clinical Setting. Indian J Chest Dis Allied Sci 2021; 63 (1):29-32.

DOI: 10.5005/ijcdas-63-1-29

License: CC BY-NC 4.0

Published Online: 18-11-2022

ARTICLE
REFERENCES

Abstract

Background: Current pharmacological management for patients with chronic obstructive pulmonary disease (COPD) focuses on inhaled long-acting bronchodilators, which are considered as the recommended first-line treatment option for such patients. Methods: A prospective study was conducted in 70 patients with moderate to severe COPD. Thirty-five patients (Group A) were administered daily glycopyrronium bromide (50ìg) and 35 (Group B) received tiotropium bromide (18ìg). Patients were assessed for forced expiratory volume in one second (FEV1) score, COPD assessment scale (CAT), modified Medical Research Council (mMRC) scale, body-mass index, airflow obstruction, dyspnoea and exercise (BODE) index for COPD survival for two consecutive follow-ups after every three months of drug use. Results: Group A showed a significant improvement with respect to different evaluation methods compared to group B. Significant results were observed for group A parameters were mMRC (0.0001), CAT (0.01), BODE (0.0001) and FEV1 (0.03). Conclusions: In patients with moderate to severe COPD, glycopyrronium bromide (50ìg) once daily is found to be more beneficial than tiotropium bromide (18ìg).

PDF Share

Global Initiative for Chronic Obstructive Lung Disease. GOLD, 2019, Available at URL: http://www.goldcopd.org/. Accessed on January 25, 2020.
Terence H, Cusack RP, Chaudhary N, Satia I, Kurmi OP. Under- and over-diagnosis of COPD: a global perspective.” Breathe (Sheffield, England), Eur Respir Society, 2019, Available at URL: www.ncbi.nlm.nih.gov/pmc/articles/PMC6395975/. Accessed on February 4, 2020.
Sutradhar I, Das Gupta R, Hasan M, Wazib A, Sarker M. Prevalence and risk factors of chronic obstructive pulmonary disease in bangladesh: a systematic review. Cureus 2019;28:e3970.
Dar SA, Bhat BA, Shah NN, Imtiyaz SB. The pattern of psychiatric morbidity in chronic obstructive pulmonary disease: a cross-sectional, case-control study from a tertiary care hospital in Kashmir, North India. J Neurosci Rural Pract 2019;10:65–70.
Shah T, Press VG, Huisingh-Scheetz M, White SR. COPD readmissions: addressing COPD in the era of value-based health care. Chest 2016;150:916–26.
Karner C, Cates CJ. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or longacting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;4:CD008989.
Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006;4:253–62.
Carter NJ. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs 2013;73:741–53.
Tashkin DP, Gross NJ. Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2018;13:1873–88.

PDF Share